Alfacell Preclinical Data Show Alfacell's ONCONASE(R) Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells

16 Apr 2007

·www.biospace.com

AACR

BLOOMFIELD, N.J., April 16 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL - News) today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirnase) significantly inhibits tumor growth of non-small cell lung cancer (NSCLC) and breast cancer cells.

Organizations

Tamir Biotechnology, Inc.

Indications

NeoplasmsNon-Small Cell Lung CancerBreast Cancer

Targets

Drugs

Ranpirnase

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.